Quantitative bioanalytical LC–MS/MS assay for S130 in rat plasma-application to a pharmacokinetic study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

Reference

• 1. Mármol I, Diego CS, Dieste AP et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci. 18(1), 197 (2017).
  Google Scholar
• 2. Binefa G, Moranta FR, Teule À et al. Colorectal cancer: from prevention to personalized medicine. World J. Gastroenterol. 20(22), 6786–6808 (2014).
  MedlineGoogle Scholar
• 3. Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J. Gastroenterol. 20(29), 9775–9827 (2014).
  MedlineGoogle Scholar
• 4. Mariño G, Uría JA, Puente XS et al. Human autophagins, a family of cysteine proteinases potentially implicated in cell degradation by autophagy. J. Biol. Chem. 278(6), 3671–3678 (2013).
  Google Scholar
• 5. Zhang L, Li JJ, Ouyang L et al. Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy. Cancer Lett. 373(1), 19–26 (2016). • Reports functions of Atg4 in cancer therapy.
  Medline CASGoogle Scholar
• 6. Liu PF, Leung CM, Chang YH et al. ATG4B promotes colorectal cancer growth independent of autophagic flux. Autophagy 101(8), 454–465 (2014).
  Google Scholar
• 7. Akin D, Wang SK, Habibzadegah-Tari P et al. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy 10(11), 2021–2035 (2014).
  MedlineGoogle Scholar
• 8. Rothe K, Lin H, Lin KB et al. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123(23), 3622–3634 (2014).
  Medline CASGoogle Scholar
• 9. Li M, Fu YY, Yang ZL et al. Measurement of the activity of the ATG4 cysteine proteases. Methods Enzymol. 587, 207–225 (2017).
  Medline CASGoogle Scholar
• 10. Shu CW, Madiraju C, Zhai D et al. High-throughput fluorescence assay for small-molecule inhibitors of autophagins/Atg4. J. Biomol. Screen 16(2), 174–182 (2011).
  Medline CASGoogle Scholar
• 11. Qiu ZX, Kuhn B, Aebi J et al. Discovery of fluoromethylketone-based peptidomimetics as covalent ATG4B (autophagin-1) inhibitors. ACS. Med. Chem. Lett. 7(8), 802–806 (2016).
  Medline CASGoogle Scholar
• 12. Fu YY, Hong L, Xu JC et al. Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer in vitro and in vivo. Autophagy 20, 1–17 (2018). •• Article of the pharmacodynamics of S130 both in vitro and in vivo.
  Google Scholar
• 13. Marino G, Uria JA, Puente XS et al. Human autophagins, a family of cysteine proteinases potentially implicated in cell degradation by autophagy. J. Biol. Chem. 278, 3671–3678 (2003).
  Medline CASGoogle Scholar
• 14. US FDA. Guidance for industry (2018): bioanalytical method validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM) (2018). www.fda.gov/downloads/drugs/guidances/ucm070107.pdf
  Google Scholar
• 15. Mei SL, Wan JQ, Cheng Q et al. Development, validation, and application of an UPLC–MS/MS method for norvancomycin analysis in human blood plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1072, 199–204 (2018).
  Medline CASGoogle Scholar
• 16. EMA. Guideline on bioanalytical method validation, EMEA/CHMP/EWP/192217/2009. Rev. 1 Corr. 2** Committee for Medicinal Products for Human Use (CHMP) (2011). www.ema.europa.eu/docs/en_GB
  Google Scholar
• 17. Clinical and Laboratory Standards Institute (CLSI). Mass spectrometry in the clinical laboratory: general principles and guidances; approved guideline, CLSI document C50-A. Wayne, PA, Clinical and Laboratory Standards Institute (2007). https://clsi.org/media/1352/c50a_sample.pdf
  Google Scholar
• 18. US FDA. Draft guidance for industry (2013): bioanalytical method validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation(CDER) and Research and Center for Veterinary Medicine (CVM) (2013). www.fda.gov/downloads/drugs/guidancesucm368107.pdf
  Google Scholar
• 19. Sun JL, Zhang L, Song J et al. Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography–mass spectrometry method: a study on bioavailability and dose proportionality. J. Ethnopharmacol. 148(2), 617–623 (2013).
  MedlineGoogle Scholar
• 20. Pang HX, Xue W, Shi AX et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy chinese volunteers. Clin. Drug Investig. 36(9), 713–724 (2016).
  Medline CASGoogle Scholar
• 21. Smith BP, Vandenhende FR, DeSante KA et al. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17(10),1278–1283 (2000).
  Medline CASGoogle Scholar
• 22. Akabane R, Sato T et al. Pharmacokinetics of single-dose sildenafil administered orally in clinically healthy dogs: effect of feeding and dose proportionality. J. Vet. Pharmacol. Ther. 41(3), 457–462 (2018).
  Medline CASGoogle Scholar